- Home
- ALLY vs GMAB Comparison
ALLY vs GMAB Comparison
Compare ALLY & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLY
- GMAB
- Stock Information
- Founded
- ALLY 1919
- GMAB 1999
- Country
- ALLY United States
- GMAB Denmark
- Employees
- ALLY N/A
- GMAB N/A
- Industry
- ALLY Major Banks
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ALLY Finance
- GMAB Health Care
- Exchange
- ALLY Nasdaq
- GMAB Nasdaq
- Market Cap
- ALLY 12.0B
- GMAB 13.2B
- IPO Year
- ALLY 2014
- GMAB N/A
- Fundamental
- Price
- ALLY $40.59
- GMAB $24.65
- Analyst Decision
- ALLY Buy
- GMAB Buy
- Analyst Count
- ALLY 18
- GMAB 6
- Target Price
- ALLY $43.47
- GMAB $37.60
- AVG Volume (30 Days)
- ALLY 2.6M
- GMAB 1.2M
- Earning Date
- ALLY 10-17-2025
- GMAB 08-07-2025
- Dividend Yield
- ALLY 2.96%
- GMAB N/A
- EPS Growth
- ALLY N/A
- GMAB 77.72
- EPS
- ALLY 1.04
- GMAB 21.62
- Revenue
- ALLY $6,852,000,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- ALLY $19.73
- GMAB $21.64
- Revenue Next Year
- ALLY $14.44
- GMAB $15.57
- P/E Ratio
- ALLY $39.15
- GMAB $1.14
- Revenue Growth
- ALLY 1.11
- GMAB 32.97
- 52 Week Low
- ALLY $29.52
- GMAB $17.24
- 52 Week High
- ALLY $43.86
- GMAB $27.94
- Technical
- Relative Strength Index (RSI)
- ALLY 67.04
- GMAB 67.82
- Support Level
- ALLY $37.62
- GMAB $21.00
- Resistance Level
- ALLY $39.20
- GMAB $22.90
- Average True Range (ATR)
- ALLY 0.81
- GMAB 0.43
- MACD
- ALLY 0.20
- GMAB 0.24
- Stochastic Oscillator
- ALLY 95.10
- GMAB 95.31
About ALLY Ally Financial Inc.
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.